do not appear to interact significantly with immediate release levodopa, but they may reduce the bioavailability of modified release preparations of levodopa
(e.g. A MadoparCR).
Concurrent use need not be avoided with standard preparations. With modified- release preparations it would seem advisable to avoid concurrent administration
(2 to 3 hours is usually enough in other similar situations). The outcome should be monitored.